The Role of the Intestinal Mycobiome in Alcoholic Liver Disease
The Role of the Intestinal Mycobiome in Alcoholic Liver Disease
批准号:
10296622
负责人:
Bernd G. Schnabl
金额:
$54.25万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-06-01 至 2027-03-31
关键词:
Adoptive TransferAffectAlcohol abuseAlcohol consumptionAlcoholic Liver DiseasesAlcoholismAlcoholsAnimal ModelAntifungal AgentsAntigensBacteriaBelgiumBindingBlood CirculationCD4 Positive T LymphocytesCaliforniaCandidaCandida albicansCellsChronicDataDeveloped CountriesDiseaseEthanolEtiologyExperimental Animal ModelFunctional disorderGermanyGoalsHealthHepaticHumanImmune responseImmunityInfrastructureInstitutesInterdisciplinary StudyInterleukin-17InterventionIntestinal permeabilityIntestinesKupffer CellsLaboratoriesLeadLigationLiverLiver diseasesMalasseziaMediatingMedicalMethodsMolecularMorbidity - disease rateMusNatural ImmunityNaturePatientsPersonsPharmacologyPortal vein structurePrincipal InvestigatorResearchResearch PersonnelRibosomal DNARoleSteatohepatitisSupplementationT cell responseT-Cell ReceptorTestingTherapeutic InterventionTransgenic MiceUnited StatesUniversitiesUniversity HospitalsVirulence FactorsVirusadaptive immunityalcohol responsealcohol use disorderbacteriomebasecohortdesigndysbiosisfeedingfungal microbiotafungusgut microbiomegut-liver axisinnovationinsightliver inflammationliver injurymacrophagemicrobialmicrobiome researchmicrobiome sequencingmicrobiotamigrationmortalitymouse dectin-2mouse modelmycobiomenew therapeutic targetnovelpreventpreventive interventionreceptor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Alcohol associated health problems are a major medical burden in industrialized countries. Patients with
alcohol-associated liver disease show intestinal bacterial dysbiosis and increased intestinal permeability.
Although there is considerable progress in understanding the interaction between the host and intestinal
bacteria, the role of the intestinal fungal microbiome (also called mycobiome) in alcohol-associated liver
disease is not very well understood. Results from our laboratories indicate a proportional increase of
Candida albicans (C. albicans) and Malassezia restricta (M. restricta) in patients with alcohol use disorder.
Results from chronic ethanol administration in mice or chronic alcohol abuse in patients show that
C. albicans-specific T cell responses occur in the intestine. CD4+ T cells re-circulate to the liver, where they
re-activate by translocated C. albicans antigens, produce interleukin 17 (IL17) and contribute to progression
of ethanol-induced steatohepatitis. In addition, products from M. restricta translocate from the gut lumen to
the systemic circulation and liver. M. restricta induces liver inflammation via ligation with the Dectin-2
(Clec4n) receptor on Kupffer cells and augments ethanol-induced liver disease in mice. The testable central
hypothesis of this proposed collaborative and multidisciplinary research application implicates disturbances
in the gut fungal mycobiota as an important etiological factor in the modulation of adaptive and innate
immunity in the liver. Through the proposed study, we will characterize the host gut mycobiome and
immune response in a human cohort. We will mechanistically test our hypothesis in a mouse model of
ethanol-induced liver disease. Towards this goal, we will use pharmacological interventions,
supplementation of fungi and genetically modified mice. We predict that two pathogenic factors contribute to
dysfunction of the gut-liver axis in alcohol-associated liver disease: C. albicans overgrowth drives Th17 cell
expansion contributing to liver inflammation and damage (Aim 1). Binding of M. restricta to Dectin-2 induces
hepatic inflammation and exacerbates alcohol-associated liver disease (Aim 2). We believe these studies
will provide important insights into alcohol-mediated changes of the intestinal mycobiome that result in an
immune response contributing to alcohol-associated liver disease. Eventually this approach might lead to
new therapeutic targets for patients with alcohol-associated liver disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Enrichment Program
-
批准号:10395970
-
项目类别:
-
资助金额:$2.48万
-
财政年份:2019
-
负责人:Bernd G. Schnabl
-
依托单位:
Administrative Core
-
批准号:10395969
-
项目类别:
-
资助金额:$18.64万
-
财政年份:2019
-
负责人:Bernd G. Schnabl
-
依托单位:
Enrichment Program
-
批准号:10617216
-
项目类别:
-
资助金额:$2.46万
-
财政年份:2019
-
负责人:Bernd G. Schnabl
-
依托单位:
Administrative Core
-
批准号:10617214
-
项目类别:
-
资助金额:$18.64万
-
财政年份:2019
-
负责人:Bernd G. Schnabl
-
依托单位:
The role of pathobionts in alcoholic liver disease
-
批准号:10363227
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Bernd G. Schnabl
-
依托单位:
The role of Enterococcus faecalis in alcoholic liver disease
-
批准号:10046278
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Bernd G. Schnabl
-
依托单位:
The role of Enterococcus faecalis in alcoholic liver disease
-
批准号:10292950
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Bernd G. Schnabl
-
依托单位:
The Role of the Intestinal Mycobiome in Alcoholic Liver Disease
-
批准号:9900694
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2017
-
负责人:Bernd G. Schnabl
-
依托单位:
The Role of the Intestinal Mycobiome in Alcoholic Liver Disease
-
批准号:10652248
-
项目类别:
-
资助金额:$49.93万
-
财政年份:2017
-
负责人:Bernd G. Schnabl
-
依托单位:
The Commensal Microflora Suppresses Liver Fibrosis
-
批准号:8814609
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Bernd G. Schnabl
-
依托单位:
The Commensal Microflora Suppresses Liver Fibrosis
-
批准号:8975084
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Bernd G. Schnabl
-
依托单位:
Microbiome and intestinal innate immune response in alcoholic liver disease
-
批准号:8889175
-
项目类别:
-
资助金额:$37.59万
-
财政年份:2011
-
负责人:Bernd G. Schnabl
-
依托单位:
Microbiome and Intestinal Innate Immune Response in Alcoholic Liver Disease
-
批准号:10658856
-
项目类别:
-
资助金额:$42.26万
-
财政年份:2011
-
负责人:Bernd G. Schnabl
-
依托单位:
Microbiome and intestinal innate immune response in alcoholic liver disease
-
批准号:8499172
-
项目类别:
-
资助金额:$36.04万
-
财政年份:2011
-
负责人:Bernd G. Schnabl
-
依托单位:
Microbiome and intestinal innate immune response in alcoholic liver disease
-
批准号:9322606
-
项目类别:
-
资助金额:$34.88万
-
财政年份:2011
-
负责人:Bernd G. Schnabl
-
依托单位:
Microbiome and intestinal innate immune response in alcoholic liver disease
-
批准号:9174353
-
项目类别:
-
资助金额:$34.88万
-
财政年份:2011
-
负责人:Bernd G. Schnabl
-
依托单位:
Microbiome and intestinal innate immune response in alcoholic liver disease
-
批准号:8337297
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2011
-
负责人:Bernd G. Schnabl
-
依托单位:
Microbiome and intestinal innate immune response in alcoholic liver disease
-
批准号:8693881
-
项目类别:
-
资助金额:$37.59万
-
财政年份:2011
-
负责人:Bernd G. Schnabl
-
依托单位:
Microbiome and intestinal innate immune response in alcoholic liver disease
-
批准号:8200205
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2011
-
负责人:Bernd G. Schnabl
-
依托单位:
Microbiome and Intestinal Innate Immune Response in Alcoholic Liver Disease
-
批准号:10454768
-
项目类别:
-
资助金额:$42.26万
-
财政年份:2011
-
负责人:Bernd G. Schnabl
-
依托单位:
海外基金